Product Image

Estroven Mood Boost

Estroven
4.6
★ ★ ★ ★ ★
(190 ratings)
Ginkgo
Product Image
Score64
A menopause-and-mood formula with some ginkgo-based cognitive relevance. It is not a focused vision product and requires medication and health-context review.
How scoring works
Quantity:30 Tablet(s) • (30 servings)
Goals:
Mental Focus
Cognitive Support
Brain Health

Score 64

A menopause-and-mood formula with some ginkgo-based cognitive relevance. It is not a focused vision product and requires medication and health-context review.
How scoring works
$15.69($0.52 per serving)
iHerb
$ 15.69
Pure Formulas
$ 17.69
Vitacost
$ 15.69
Vitacost
$ 15.69
Report prices

Analysis

The tablet combines 120 mg ginkgo with black cohosh, soy isoflavones, and magnolia bark. Its design fits menopause and mood support better than brain performance or vision.

Ginkgo provides the main cognitive pathway through circulation, while magnolia may support calm. The remaining actives do not supply macular carotenoids, retinal lipids, or foundational eye nutrients.

Ginkgo lacks active-marker percentages and a ginkgolic-acid limit, while black cohosh standardization is also not shown. Soy and black cohosh make hormone-sensitive and liver-related suitability important.

Who is it for
  • Adults seeking menopause and mood support after appropriate review
  • Users who tolerate soy ingredients
  • People not primarily seeking vision nutrition
Best for
  • Menopause-related mood routines
  • Users specifically seeking black cohosh with soy isoflavones
  • Clinician-reviewed botanical use

Pros

  • All main active amounts are disclosed
  • Provides a practical ginkgo amount
  • Magnolia adds a calm-support pathway

Cons

  • Poor alignment with vision
  • Ginkgo standardization is incomplete
  • Contains soy
  • No macular or retinal nutrients

Warnings

  • Ginkgo may add to anticoagulant or antiplatelet effects and increase bleeding risk
  • Black cohosh warrants caution with liver disease or unexplained dark urine, jaundice, or abdominal pain
  • Soy isoflavones and black cohosh require review in hormone-sensitive conditions or with hormone-related medicines

Nutrient quality

60 Moderate impact

The ginkgo amount is useful and the additional botanicals support a clear menopause use case. Unspecified forms and weak alignment with the listed goals limit nutrient quality.

.

Ingredient transparency

76 High impact

Active amounts are disclosed without a proprietary blend. Most extract specifications, daily-use directions, and non-active ingredients are missing.

.

Customer satisfaction

62 Moderate impact

The available rating is favorable and the sample is moderate. Detailed feedback was not supplied, so repeated complaints and alignment with the intended use remain uncertain.

.

Value for money

53 Moderate impact

The short supply provides only modest value for the disclosed quality. Menopause-focused extras add cost without strong alignment to the configured goals.

.
Report analysis

Goals

Mental Focus
Mental Focus
Impact
Moderate effect
C+ Goal FitC Strength of SupportC- CoverageD+ Formula Quality

Ginkgo provides the clearest focus-related ingredient at a commonly used amount. Missing standardization for key ginkgo compounds limits confidence in potency and evidence matching.

Magnolia may support stress balance, while black cohosh and soy mainly address menopausal symptoms rather than attention. The formula may suit mood-related concentration concerns but is not a clean, acute focus blend.

Study evidence
Ginkgo Supportive 28 studies
Cognitive Support
Cognitive Support
Impact
Moderate effect
C+ Goal FitC- Strength of SupportC- CoverageD+ Formula Quality

The 120 mg ginkgo extract provides a direct circulation-based link to memory and attention. Magnolia may support calmness, but the broader formula is designed more for menopausal mood support than cognition.

Missing ginkgo standardization prevents confirmation of the active flavone and terpene yields. Ginkgo may increase bleeding risk when combined with anticoagulant or antiplatelet medicines.

Study evidence
Ginkgo Supportive 87 studies
Brain Health
Brain Health
Impact
Moderate effect
C- Goal FitD+ Strength of SupportC- CoverageC- Formula Quality

Ginkgo provides a relevant circulation-based cognitive pathway, while magnolia may support calm during menopause. The broader black cohosh and soy formula is primarily aimed at menopausal symptoms rather than brain health.

The ginkgo amount is clear, but active-marker standardization and a ginkgolic-acid limit are not supplied. Ginkgo may increase bleeding risk with anticoagulants or antiplatelet medicines, and black cohosh warrants caution with liver disease.

Study evidence
Ginkgo Supportive 90 studies

Ingredients

IngredientAmount per serving
Total Carbohydrates
1 Gram(s)
Calcium (Dicalcium Phosphate)
 95 mg
Black Cohosh root extract
40 mg
Soy Isoflavones
56 mg
Ginkgo biloba leaf extract
120 mg
Magnolia bark extract
15 mg
Women Women 18–50 Menopause
Report overview
Ginkgo · 120 mg OverallScore35
F Active Ingredient Quality & BioavailabilityB+ Dose, Safety & Label TransparencyF Value

The listed 120 mg Ginkgo extract matches a commonly used daily amount, but the label does not confirm key active-marker standardization. The dose is clearly disclosed, while the lack of ginkgolic acid limits or a recognized branded extract leaves purity uncertain. Cost efficiency is difficult to support because the effective standardized amount cannot be verified.

View ingredientView products
Loading alternative details
83 Performance

Ginkgold 120 mg

Nature's Way
A 120 mg Ginkgold extract identified by flavone glycosides and terpene lactones offers a focused, substantial ginkgo dose. Exact marker percentages and a ginkgolic-acid limit are not supplied, so extract characterization is still incomplete.
84 Performance

Ginkgo Biloba Phytosome 60 mg

Natural Factors HerbalFactors
A 60 mg Ginkgoselect phytosome uses a distinct delivery format that may suit someone prioritizing a compact dose. The supplied label does not state flavone, terpene, or ginkgolic-acid details, which limits direct potency comparison.
84 Performance

Ginkgo Biloba 120 mg

California Gold Nutrition EuroHerbs
A concise 120 mg extract identified by flavone glycosides and terpene lactones provides stronger dose depth than many 40 mg or 60 mg formulas. Marker percentages and a ginkgolic-acid limit are not shown, but the simple formula supports clear comparison.
83 Budget

Ginkgo Biloba 60 mg

NOW
A lower recurring cost provides a 60 mg extract identified by ginkgo flavone glycosides and terpene lactones plus 200 mg of ginkgo powder. Marker percentages are not stated, but the added powder and long supply provide useful depth for the cost.
84 Budget

Ginkgo Biloba Certified Extract 120 mg

Life Extension
A lower recurring cost provides 120 mg of ginkgo with flavone glycosides, terpene lactones, and a stated low ginkgolic-acid limit. Exact marker percentages are not shown, while the impurity limit and long supply improve practical quality.
83 Budget

Ginkgo Biloba 60 mg

Swanson Superior Herbs
A lower recurring cost provides a branded 60 mg GinkgoSelect extract identified by flavone glycosides and terpene lactones. The marker percentages are missing, but the focused formula remains easy to assess and inexpensive to use.
84 Value

Ginkgo Biloba 120 mg

California Gold Nutrition EuroHerbs
A lower serving cost than the original accompanies the following trade-off: a 120 mg ginkgo extract identified by flavone glycosides and terpene lactones combines a substantial dose with a long supply. The missing marker percentages and ginkgolic-acid limit are the main quality gaps.
80 Value

Double Strength Ginkgo Biloba 120 mg

NOW
A lower serving cost than the original accompanies the following trade-off: a 120 mg ginkgo extract identified by flavone glycosides and terpene lactones is paired with 250 mg of eleuthero at a low serving cost. Exact ginkgo marker percentages are absent, and eleuthero makes the formula less focused than a single-ingredient option.
80 Value

Ginkgo-24 120 mg

Source Naturals
A lower serving cost than the original accompanies the following trade-off: a simple 120 mg ginkgo extract identifies both flavone glycosides and terpene lactones at a moderate serving cost. The label does not state exact marker percentages or a ginkgolic-acid limit.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
    Herrschaft H; Nacu A; Likhachev S; Sholomov I; Hoerr R; Schlaefke S · Journal of psychiatric research · 2012
    Randomized trial410 participantsBrain Health forGinkgo
  2. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial.
    van Dongen M; van Rossum E; Kessels A; Sielhorst H; Knipschild P · Journal of clinical epidemiology · 2003
    Randomized trial214 participantsBrain Health forGinkgo
  3. Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials.
    Feng JX; Zheng MQ; Tian X; Zimmermann A; Wang AX; Meng X · Frontiers in neurology · 2026
    Meta-analysis488 participants4 studies pooledBrain Health forGinkgo
  4. Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
    von Gunten A; Schlaefke S; Überla K · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017
    Meta-analysis1,628 participants4 studies pooledCognitive Support Brain Health forGinkgo
  5. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P · Drugs & aging · 2019
    Meta-analysisCognitive Support forGinkgo
  6. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.
    Bachinskaya N; Hoerr R; Ihl R · Neuropsychiatric disease and treatment · 2011
    Randomized trial410 participantsCognitive Support forGinkgo
  7. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
    Tan MS; Yu JT; Tan CC; Wang HF; Meng XF; Wang C; Jiang T; Zhu XC; Tan L · Journal of Alzheimer's disease : JAD · 2015
    Meta-analysis2,561 participants9 studies pooledBrain Health forGinkgo
  8. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
    Riepe M; Hoerr R; Schlaefke S · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2025
    Meta-analysis782 participants4 studies pooledBrain Health forGinkgo
  9. Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
    Cui M; You T; Zhao Y; Liu R; Guan Y; Liu J; Liu X; Wang X; Dong Q · Frontiers in pharmacology · 2023
    Randomized trial201 participantsBrain Health forGinkgo
  10. Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.
    Tian X; Xu Q; Xia X; Zhang Y; Meng X; Wang A · Journal of neurology · 2024
    Randomized trial3,163 participantsCognitive Support forGinkgo
  11. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF · JAMA · 1997
    Randomized trial309 participantsCognitive Support forGinkgo
  12. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
    Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O; GOTADAY Study Group · International journal of geriatric psychiatry · 2013
    Randomized trial410 participantsCognitive Support forGinkgo
  13. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
    Hort J; Duning T; Hoerr R · Neuropsychiatric disease and treatment · 2023
    Systematic review946 participants9 studies pooledMental Focus forGinkgo
  14. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2012
    Randomized trial216 participantsMental Focus forGinkgo
  15. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Pharmacopsychiatry · 1996
    Randomized trial216 participantsMental Focus forGinkgo
  16. Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial.
    Li S; Zhang X; Fang Q; Zhou J; Zhang M; Wang H; Chen Y; Xu B; Wu Y; Qian L; Xu Y · Stroke and vascular neurology · 2021
    Randomized trial348 participantsMental Focus forGinkgo
  17. Ginkgo biloba in the Aging Process: A Narrative Review.
    Barbalho SM; Direito R; Laurindo LF; Marton LT; Guiguer EL; Goulart RA; Tofano RJ; Carvalho ACA; Flato UAP; Capelluppi Tofano VA; Detregiachi CRP; Bueno PCS; Girio RSJ; Araújo AC · Antioxidants (Basel, Switzerland) · 2024
    Narrative review14 studies pooledMental Focus forGinkgo